Electra Therapeutics, Inc. — Form 4
Filed September 23, 2026 · analyzed by the Insider Agent
4
▲ Likely positive
significance 78/100
What the filing says
Director GORDON CARL L (ETRA) bought 6.9M shares (~$20.0M) on the open market (80% of holdings). Open-market insider purchase — historically a bullish signal.
Why this rating
Open-market insider purchase — historically a bullish signal.
Tradability signal
NO TRADE
No trade: positive news with only -2.4% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.19% over 4 hrs, n=109). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $12.90 ▲ 1.84% | at our read · unknown $12.67 | +10 min · unknown $12.26 ▼ 3.28% | +30 min · unknown $12.45 ▼ 1.74% | +1 hr · unknown $12.74 ▲ 0.55% | +4 hrs · unknown $12.51 ▼ 1.30% |
The stock had already moved -1.81% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.